Newsroom

Sorted by: Latest
-

DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Results from three trials continue to demonstrate the potential of DATROWAY® (datopotamab deruxtecan) in combination with various immunotherapies to improve outcomes in patients with non-small cell lung cancer (NSCLC) across multiple stages of the disease. These results from TROPION-Lung02, TROPION-Lung04 and NeoCOAST-2 were presented at the 2025 American Society of Clinical Oncology (#ASCO25) Annual Meeting. DATROWAY is a specifically engineered TR...
-

Announcing Balaji Karumanchi as Founder & CEO of Excelhire – The AI-Agentic Hiring Intelligence Platform

FRISCO, Texas--(BUSINESS WIRE)--Excelhire, the AI-powered hiring intelligence platform, proudly announces Balaji Karumanchi as its Founder and Chief Executive Officer....
-

Introducing Tempus One in the EHR with Integrated Guidelines

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of Tempus One—its generative AI clinical assistant—with direct integration into electronic health record (EHR) systems. By integrating AI at every point of the clinical care process, the expanded capabilities of Tempus One offer physicians in oncology and beyond more support in treatment decisions. Tempus One is un...
-

IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) versus chemotherapy alone. Patients were treated with neoadjuvant IMFINZI in combination with che...
-

Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the SERENA-6 Phase III trial showed that AstraZeneca’s camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS). The trial evaluated switching to the camizestrant combination versus continuing standard-of-care treatment with an aromatase inhibitor (AI) (anas...
-

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. The data will be presented as a late-breaking oral presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeti...
-

Research Presented by The US Oncology Network at ASCO 2025 Demonstrates Significant Cost Savings in Community Oncology Setting with Pharmacist-Driven Interventions

THE WOODLANDS, Texas--(BUSINESS WIRE)--At ASCO 2025, The US Oncology Network explores the impact of engaging a remote clinical pharmacist in reducing the total cost of care within the EOM....
-

Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced real-world data evaluating the safety and effectiveness of Yescarta® (axicabtagene ciloleucel) for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) assigned to treatment in an outpatient setting (no planned hospital stay) versus those assigned to an inpatient setting in a hospital. The analysis, based on data collected from the Center for International Blood and Marrow Transplant Rese...
-

Hibiki Path Advisors Launch a Public Campaign as the Largest Shareholder of JAPAN PURE CHEMICAL CO., LTD.

TOKYO--(BUSINESS WIRE)--Hibiki Path Advisors (“we”, “us”, “our”) has decided to launch a public campaign, including shareholder proposals, directed at one of our portfolio companies, JAPAN PURE CHEMICAL CO., LTD. (Securities Code: 4973) (hereinafter referred to as “the Company”, “JPC”), in the lead-up to its 54th Annual General Meeting of Shareholders scheduled for 20th June 2025. As the largest shareholder of the Company, our aim with this campaign is to protect and enhance the common interest...
-

ひびき・パース・アドバイザーズは日本高純度化学株式会社に対する筆頭株主としての公開キャンペーンを実施いたします

TOKYO--(BUSINESS WIRE)--（ビジネスワイヤ） -- Hibiki Path Advisors（以下、「私ども」といいます。）は、投資先の一社である日本高純度化学株式会社(証券コード：4973)（以下、「当社」といいます。）に対し、2025年6月20日開催予定の第54期株主総会に向けて、筆頭株主の立場から当社全株主共同の利益を確保するべく、株主提案を含む公開キャンペーンを実施する事を決定いたしました。 当社が上程する渡辺取締役相談役の再任への反対 尚、その他取締役候補につき、小島智敬氏、黒松百亜氏を除く８名（補欠を含む）に対し反対を予定（※１） 当社が上程する監査等委員会設置会社への移行への反対を予定（※1） 株主提案（第10号議案）：取締役(社外取締役を除く)に対する株式報酬の強化 株主提案（第11号議案）：剰余金の配当等の決定機関に関する定款一部変更の件 株主提案（第12号及び13号議案）：ROE向上に向けた株主還元の強化（自己株式取得、配当の強化） ※１ ①及び②に関して予定としている理由については、添付趣意書をご参照下さい。 尚、公開キャンペーンの詳細につ...